Lipoprotein(a) [Lp(a)], anti-Human
| Product Name | anti-Human Lipoprotein(a) |
| Source | Polyclonal Antibody |
| Catalogue Number | 400-45 |
| Purity | Affinity Purified |
| Form | Liquid |
| Host | Sheep |
| Concentration | 0.5 - 2.0 mg/mL (A280nm) |
| Immunogen | High purity human Lp(a) |
| Reactivity | Human Lp(a), no cross-reactivity to ApoB. |
| Conjugate | Unconjugated |
| Formulation | Solution in sodium phosphate, sodium chloride, EDTA and 0.02% sodium azide and 30% glycerol, pH 7.2. |
| Related Products | 400-42 - Lipoprotein (a) antigen from human plasma 125-25 - Apolipoprotein B from human plasma - >80% (SDS-PAGE) 125-26 - Goat anti-Human Apolipoprotein B Polyclonal Antibody |
| Storage | -20°C |
| Recertification | 1 year |
| Synonyms | Lp(a), LPA, AK38, APOA, LP |
Custom preparations, technical support, bulk quantities and aliquoting available, email Info@leebio.com for more details.
Introduction
Lipoprotein(a) [Lp(a)] is a unique lipoprotein that has emerged as an independent risk factor for developing vascular disease. Lp(a) is structurally similar to LDL but contains Apolipoprotein(a) (Apo(a)) in addition to Apolipoprotein B-100 (ApoB-100)1. Initially synthesized in the liver, Lp(a) circulates in the bloodstream to transport cholesterol and fats to other organs. Lp(a) can promote inflammation, foam cell formation, and thrombosis 2. Several studies have shown positive associations between elevated Lp(a) levels and increased risk of coronary heart disease/cardiovascular disease. Genetics have the most impact in an individual’s concentrations of Lp(a) and thus play a significant role in risk for premature development of coronary heart disease/cardiovascular disease 3,4.
Diagnostic Relevance
Normal levels of Lp(a) in the blood are less than 30 mg/dL; however, over 20% of adults in the United States have Lp(a) levels of >50 mg/dL3. Elevated levels of Lp(a) are associated with increased risk of coronary heart disease, cerebrovascular disease, atherosclerosis, thrombosis, and stroke.
Identification
1.Synonyms: Lp(a), LPA, AK38, APOA, LP
2.Accession #:
a.P08519 (Apo(a))
b.P04114 (ApoB-100)
3.Gene:
a.Apo(a) gene [LPA] located on chromosome 6q26-27.
b.ApoB-100 gene [APOB] located on chromosome 2p24.
Properties
1.Structure: One molecule of ApoB-100 wrapped around a core of cholesteryl ester, triglyceride, phospholipids, and unesterified cholesterol. Apo(a) is covalently bound to the ApoB-100 through a disulfide bridge 5, 6.
2.Composition: 65% lipid, 27% protein, 8% carbohydrate.
3.Post-Translational Modification:
a.Apo(a): Autocatalytic cleavage, formation of disulfide bond, glycosylation
b.ApoB-100: Acetylation, formation of disulfide bond, glycosylation, lipidation, palmitoylated
4.Extinction Coefficient:
a.ApoB-100: E0.1%280nm = 0.79
5.Function:
a.Apo(a) is the main constituent of Lp(a). It has serine protease activity and is capable of autoproteolysis. Inhibits tissue-type plasminogen activator. (E.C. 3.4.21.-)
b.ApoB-100 functions as a recognition signal for the cellular binding and internalization of LDL particles by the ApoB/E receptor.
6.Molecular Weight:
a.Lipoprotein(a): approximately 1,000,000
b.Apo(a): approximately 250,000 to 800,000
c.ApoB-100: approximately 515,000
7.Stability: Stable as liquid at 2 – 8 °C. Recertification required one year after DOM. Avoid repeated freeze thaws.
8.Density: 1.05 – 1.12 g/mL 7.
References
1.Utermann, G. (1989) The mysteries of lipoprotein(a). Science 246, 904-910.
2.Erqou, S., Kaptoge, S., Perry, P. L., Di Angelantonio, E., Thompson, A., White, I. R., Marcovina, S. M., Collins, R., Thompson, S. G., and Danesh, J. (2012) Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. The Journal of the American Medical Association (JAMA). 302, 412-423.
3.Nordestgaard, B. G., Chapman, M. J., Ray, K., Boren, J., Andreotti, F., Watts, G. F., Ginsberg, H., Amarenco, P., Catapano, A., Descamps, O. S., Fisher, E., Kovanen, P. T., Kuivenhoven, J. A., Lesnik, P., Masana, L., Reiner, Z., Taskinen, M. R., Tokgozoglu, L., and Tybjærg-Hansen, A. (2010) Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J. 31, 2844-2853.
4.Raal, F. J., Giugliano, R. P., Sabatine, M. S., Koren, M. J., Blom, D., Seidah, N. G., Honarpour, N., Lira, A., Xue, A., Chiruvolu, P., Jackson, S., Di, M., Peach, M., Somaratne, R., Wasserman, S. M., Scott, R., and Stein, E. A. (2016) PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor’s role. J Lipid Res. 57, 1086-1096.
5.Marconiva, S. M. and Albers, J. J. (2016) Lipoprotein (a) measurements for clinical application. Journal of Lipid Research. 57, 526-537.
6.Gaubatz, J. W., Heideman, C., Gotto, A. M., Jr., Morrisett, J. D., and Dahlen, G. H. (1982) Human Plasma Lipoprotein [a]. J. Biol. Chem. 258, 4582-4589.
7.Maranhao, R. C., Carvalho, P. O., Strunz, C. C., and Pileggi, F. (2014) Lipoprotein (a): Structure, Pathophysiology, and Clinical Implications. Arq Bras Cardiol. 103, 76-84.
Lee Biosolutions, Inc
